Intravenous and oral administrations of DD2 [7-Amino-2-(sulfanylmethyl)heptanoic acid] produce thrombolysis through inhibition of plasma TAFIa in rats with tissue factor-induced microthrombosis.
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen that is activated by thrombin in plasma. In fibrinolytic processes, carboxy-terminal lysine (Lys) residues in partially degraded fibrin are important sites for plasminogen binding and activation, and an active form of TAFI (TAFIa) inhibits fibrinolysis by eliminating these residues proteolytically. We synthesized DD2 [7-Amino-2-(sulfanylmethyl)heptanoic acid], a Lys analogue containing sulfur, as an inhibitor of TAFIa and investigated its pharmacological profile and pathophysiological role in thrombolysis via in vitro and in vivo studies. DD2 specifically inhibited plasma TAFIa activity with an apparent IC(50) (50% inhibitory concentration) value of 3.4×10(-8)M under the present experimental condition and enhanced tissue plasminogen activator-mediated clot lysis in a concentration-dependent manner. In order to study tissue factor (TF)-induced microthrombosis in an animal model, rats were given intravenous injection (2.5mg/kg and higher) or oral administration (10mg/kg and higher) of DD2. This attenuated TF-induced glomerular fibrin deposition and increased the plasma levels of fibrin degradation products and D-dimer in a dose-dependent manner. A DD2 dose approximately 4X higher than the dose used in intravenous injections was required to achieve an equivalent thrombolytic effect to that seen following oral administration. Moreover, the oral absorption efficiency of DD2 into the vasculature was 29.8%. These results indicate that both intravenous and oral administration of DD2 enhanced endogenous fibrinolysis and reduced thrombi in a TF-induced microthrombosis model.
High Technology Research Center, Showa Pharmaceutical University, 3-3165 Higashi Tamagawa Gakuen, Machida, Tokyo 194-8543, Japan.
Tomoyuki
T
Sasaki
Nobuko
N
Yoshimoto
Katsuyoshi
K
Sugimoto
Kimihiko
K
Takada
Norie
N
Murayama
Hiroshi
H
Yamazaki
Keiko
K
Yamamoto
Hidemi
H
Ishii
D061605:Administration, Intravenous; D000284:Administration, Oral; D000596:Amino Acids / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D025901:Carboxypeptidase B2 / Q000037:antagonists & inhibitors* / Q000097:blood; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D008239:Lysine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D008297:Male; D051381:Rats; D013457:Sulfur Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D013925:Thromboplastin; D013927:Thrombosis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology
D000596:Amino Acids; D005343:Fibrinolytic Agents; D013457:Sulfur Compounds; D013925:Thromboplastin; C018819:omega-aminoenantic acid; D025901:Carboxypeptidase B2; D008239:Lysine